we are well on our way to providing much needed international access to nephrologists for use with patients in need
Philadelphia, Pennsylvania (PRWEB) January 15, 2013
In a move to expand its geographic reach to international markets and further implement the strategic growth plan of the company, Pentec Health, Inc. today announced that it has been awarded a patent by the Intellectual Property Office of the United Kingdom for its speciality pharmacy compounded prescription renal formulation, PROPLETE®.
Pentec’s geographic expansion is viewed by the company as an engine for future growth. The patent is the company’s first in Europe. Pentec is currently pursuing patents for PROPLETE® in multiple other countries, including the United States. Pentec provides PROPLETE® as a pharmacy compounding service to nephrologists who prescribe patient specific renal nutrition. Pentec’s compounding services are available in all 50 U.S. states.
“This terrific news is very much in line with our three-pronged approach for geographic expansion,” explains Joseph Cosgrove, Pentec’s Chairman and CEO. “When I joined Pentec, we were primarily a regionally focused company, and in three years we achieved national status. Gaining international footing was the next hurdle, and now with the grant of a patent to PROPLETE® in the United Kingdom, we are well on our way to providing much needed international access to nephrologists for use with patients in need.”
Pentec is a large specialty infusion compounding pharmacy focused on providing innovative and proprietary compounding services for patients suffering from chronic renal failure and highly complex therapies for patients with intrathecal pumps in the United States. The company will proudly celebrate its 30th anniversary in May of this year.
About Pentec Health, Inc.
Pentec Health Inc. is a privately held specialty infusion services and healthcare technology company headquartered in suburban Philadelphia. Cutting edge innovations in patient care allow Pentec Health to provide products and services to underserved patient populations. The Joint Commission has consistently awarded Pentec with a Gold Seal of Approval for their commitment to providing the highest level of patient safety and patient care for renal nutritional and specialty infusion home care services. Pentec's renal nutrition business specializes in providing patient-specific, proprietary nutritional therapies for patients suffering from chronic kidney disease. Pentec's specialty infusion business provides in-home care for patients with implanted drug delivery pumps treating severe pain and/or spasticity. Pentec's award-winning executives are noted for top leadership and giving back to the communities in which they serve. For more information, visit http://www.pentechealth.com